PMID- 31960563
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Print)
IS  - 1478-3223 (Linking)
VI  - 40
IP  - 5
DP  - 2020 May
TI  - Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 
      diabetes.
PG  - 1089-1097
LID - 10.1111/liv.14385 [doi]
AB  - BACKGROUND & AIMS: Studies have described prominent histologic improvement in 
      patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); 
      however, these were all short term with moderate sample size, no liver-related 
      long-term outcomes could be noted. METHODS: This retrospective cohort study 
      enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from 
      Taiwan's National Health Insurance Research Database between 1 January 2000 and 
      31 December 2013. We matched TZD users and nonusers at a 1:1 ratio through 
      propensity score matching. This study included 5095 paired TZD users and 
      nonusers. Cox proportional hazard models were used to compare the risks of 
      cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality 
      between TZD users and nonusers. The Kaplan-Meier method was used to compare the 
      cumulative incidence of these main outcomes. RESULTS: The incidence rates of 
      cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality during 
      follow-up were 0.77 vs 1.95, 1.43 vs 1.75, 0.36 vs 0.70, and 4.89 vs 3.78 per 
      1000 person-years between TZD users and nonusers. The adjusted hazard ratios of 
      cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality were 
      0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 
      (95% CI: 0.18-1.17) and 1.18 (95% CI: 0.87-1.61) respectively. CONCLUSIONS: Our 
      study demonstrated that TZD use could significantly lower the risk of cirrhosis. 
      In clinical settings, TZD use might be able to improve liver-related long-term 
      outcomes.
CI  - (c) 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
FAU - Yen, Fu-Shun
AU  - Yen FS
AD  - Dr. Yen's Clinic, Taoyuan City, Taiwan.
FAU - Yang, Yu-Cih
AU  - Yang YC
AD  - Management Office for Health Data, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - College of Medicine, China Medical University, Taichung, Taiwan.
FAU - Hwu, Chii-Min
AU  - Hwu CM
AD  - Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, 
      Taiwan.
AD  - Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
FAU - Wei, James C-C
AU  - Wei JC
AD  - Division of Allergy, Immunology and Rheumatology Chung Shan Medical University 
      Hospital, Taichung, Taiwan.
FAU - Huang, Yi-Hsiang
AU  - Huang YH
AUID- ORCID: 0000-0001-5241-5425
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei, Taiwan.
AD  - Institute of Clinical Medicine, School of Medicine, National Yang-Ming 
      University, Taipei, Taiwan.
FAU - Hou, Ming-Chih
AU  - Hou MC
AD  - Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, 
      Taiwan.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei, Taiwan.
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
AUID- ORCID: 0000-0003-4563-4341
AD  - Institute of Population Health Sciences, National Health Research Institutes, 
      Zhunan, Taiwan.
AD  - Department of Health Services Administration, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200210
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Liver
MH  - Retrospective Studies
MH  - *Thiazolidinediones/therapeutic use
PMC - PMC7317545
OTO - NOTNLM
OT  - all-cause mortality
OT  - cirrhosis
OT  - hepatic decompensation
OT  - hepatic failure
OT  - liver-related death
OT  - nonalcoholic fatty liver disease
COIS- The authors do not have any disclosures to report.
EDAT- 2020/01/22 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/06/26
CRDT- 2020/01/22 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2020/01/12 00:00 [revised]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/01/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/22 06:00 [entrez]
PHST- 2020/06/26 00:00 [pmc-release]
AID - LIV14385 [pii]
AID - 10.1111/liv.14385 [doi]
PST - ppublish
SO  - Liver Int. 2020 May;40(5):1089-1097. doi: 10.1111/liv.14385. Epub 2020 Feb 10.